MERCK & CO Aktie

 

Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session....

Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?...

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store....

Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy....

ABU DHABI, UAE, June 24, 2026 /PRNewswire/ -- As healthcare systems worldwide seek more resilient and efficient pathways to deliver innovative medicines, the Department of Health – Abu Dhabi (DoH) has announced a collaboration with global pharmaceutical leader MSD (Merck & Co., Inc.,......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda....

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown....

In the closing of the recent trading day, Merck (MRK) stood at $113.87, denoting a -1.36% move from the preceding trading day....

Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...

In the closing of the recent trading day, Merck (MRK) stood at $120.76, denoting a +1.4% move from the preceding trading day....

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store....

KENILWORTH (NJ) (dpa-AFX) - Merck Animal Health, a division of Merck & Co. (MRK), on Thursday announced a definitive agreement to acquire TARGAN, a privately held developer of biodevice solutions ......

TARGAN's innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performanceRAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company's largest shareholders. The proposed acquisition is expected to be completed in the third quarter of 2026, subject to approvals from applicable regulatory authorities and other customary closing conditions. “The acquisition of TARGAN's best-in-class biodevice technology for use in commercial hatcheries complements and accelerates our growing biop...

MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals....

Gilead Sciences Inc. and Merck & Co. said an experimental long acting pill combining two HIV medicines had met its primary efficacy goal in final-stage trials....

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?...

Merck & Co. says it will settle a spate of lawsuits that blame the drugmaker's blockbuster Gardasil cancer vaccine for causing autoimmune ailments that affect young women's hearts and reproductive systems for an amount that is “not material” to the pharma firm....

Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat. Merck followed with a Q1 2026 report dominated by a $9 billion Cidara acquisition charge. Two very different income stories for yield hunters. One Pays You to ... Pfizer vs Merck: Chasing High Yield vs Higher Returns...

MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients....